PLoS ONE (Jan 2021)

Prognostic value of high-sensitivity cardiac troponin I in heart failure patients with mid-range and reduced ejection fraction.

  • Petr Lokaj,
  • Jindrich Spinar,
  • Lenka Spinarova,
  • Filip Malek,
  • Ondrej Ludka,
  • Jan Krejci,
  • Petr Ostadal,
  • Dagmar Vondrakova,
  • Karel Labr,
  • Monika Spinarova,
  • Monika Pavkova Goldbergova,
  • Marie Miklikova,
  • Katerina Helanova,
  • Ilona Parenicova,
  • Vladimir Jakubo,
  • Klara Benesova,
  • Roman Miklik,
  • Jiri Jarkovsky,
  • Tomas Ondrus,
  • Jiri Parenica

DOI
https://doi.org/10.1371/journal.pone.0255271
Journal volume & issue
Vol. 16, no. 7
p. e0255271

Abstract

Read online

BackgroundThe identification of high-risk heart failure (HF) patients makes it possible to intensify their treatment. Our aim was to determine the prognostic value of a newly developed, high-sensitivity troponin I assay (Atellica®, Siemens Healthcare Diagnostics) for patients with HF with reduced ejection fraction (HFrEF; LVEF Methods and resultsA total of 520 patients with HFrEF and HFmrEF were enrolled in this study. Two-year all-cause mortality, heart transplantation, and/or left ventricular assist device implantation were defined as the primary endpoints (EP). A logistic regression analysis was used for the identification of predictors and development of multivariable models. The EP occurred in 14% of the patients, and these patients had higher NT-proBNP (1,950 vs. 518 ng/l; p II, NT-proBNP, hs-cTnI and urea) was 0.823 (p Conclusionhs-cTnI levels ≥ 17 ng/l represent an independent increased risk of an adverse prognosis for patients with HFrEF and HFmrEF. Determining a patient's hs-cTnI level adds prognostic value to NT-proBNP and clinical parameters.